A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate

2016 ◽  
Vol 86 (3) ◽  
pp. 188-195 ◽  
Author(s):  
Delphine Zenaty ◽  
Joelle Blumberg ◽  
Nilani Liyanage ◽  
Evelyne Jacqz-Aigrain ◽  
Najiba Lahlou ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Efficacy And Safety ◽  
Retrospective Comparison ◽  
Triptorelin Pamoate ◽  
Triptorelin Acetate

Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study

2019 ◽  
Vol 36 (4) ◽  
pp. 338-340
Author(s):  
Stefania Lasorella ◽  
Rossella Porto ◽  
Maria Laura Iezzi ◽  
Carmelo Pistone ◽  
Gian Luigi Marseglia ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Triptorelin Pamoate ◽  
Triptorelin Acetate

scholarly journals Early puberty in end stage renal failure and renal transplant recipients

2019 ◽  
Vol 32 (6) ◽  
pp. 577-583
Author(s):  
Carmit Avnon Ziv ◽  
Shimrit Tzvi-Behr ◽  
Efrat Ben-Shalom ◽  
Choni Rinat ◽  
Rachel Becker-Cohen ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Precocious Puberty ◽  
Breast Development ◽  
Delayed Puberty ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Early Puberty ◽  
Release Formulation ◽  
Triptorelin Acetate

Abstract Background Delayed puberty and hypogonadism are common in children with chronic kidney disease and in renal transplant recipients, but precocious puberty has rarely been reported in these populations. We describe six girls with precocious and/or early-onset, rapidly progressive puberty before and following renal transplantation. Methods Of 112 children under the age of 18 years (67 boys, 45 girls) who received renal transplants between 2010 and 2018, six girls presented with precocious or rapidly progressive early puberty at ages 6–7/12, 7–2/12, 7–4/12, 8, 8–8/12 and 8–11/12 years. Clinical evaluation included measurements of height, weight, body mass index (BMI), Tanner staging and bone age assessment. Gonadotropin responses to intravenous gonadotropin releasing hormone (GnRH) or intramuscular triptorelin acetate were determined. Results Tanner breast stage 3 was noted at 2–6 years following renal transplantation in five girls, four with preserved kidney function. One girl began puberty before renal transplantation. Peak luteinizing hormone (LH) and follicular stimulating hormone (FSH) levels were 6.5, 20.2, 7.83, 19.1, 9 and 2.2 mIU/mL and 13, 8.3, 8.01, 7.5, 8.1 and 7.7 mIU/mL, respectively. Treatment with an intramuscular slow-release formulation of triptorelin acetate every 4 weeks slowed progression of breast development. Conclusions Although delayed puberty is more common in children with renal disease, precocious puberty can also be seen. Evaluation of growth and puberty by a pediatric endocrinologist should be part of the routine care for all children following kidney transplantation.

Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety

2016 ◽  
Vol 263 (4) ◽  
pp. 799-806 ◽  
Author(s):  
Flavio Bellante ◽  
Benjamin Legros ◽  
Chantal Depondt ◽  
Jacques Créteur ◽  
Fabio Silvio Taccone ◽  
...  
Keyword(s):  
Status Epilepticus ◽  
Refractory Status Epilepticus ◽  
Efficacy And Safety ◽  
Refractory Status ◽  
Retrospective Comparison

scholarly journals Efficacy and Safety of Leuprolide Acetate 3-Month Depot 11.25 Milligrams or 30 Milligrams for the Treatment of Central Precocious Puberty

2012 ◽  
Vol 97 (5) ◽  
pp. 1572-1580 ◽  
Author(s):  
Peter A. Lee ◽  
Karen Klein ◽  
Nelly Mauras ◽  
E. Kirk Neely ◽  
Clifford A. Bloch ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Leuprolide Acetate ◽  
Efficacy And Safety

Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty

2015 ◽  
Vol 28 (11-12) ◽  
Author(s):  
Onur Akın ◽  
Süleyman Tolga Yavuz ◽  
Bülent Hacıhamdioğlu ◽  
Erkan Sarı ◽  
Orhan Gürsel ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Vital Signs ◽  
Central Precocious Puberty ◽  
Pediatric Case ◽  
Severe Anaphylaxis ◽  
Systemic Reactions ◽  
Life Threatening ◽  
Lh Rh ◽  
Hands And Feet ◽  
Triptorelin Acetate

AbstractGonadotropin-releasing hormone analogues are generally regarded as safe drugs. Gonadorelin acetate has been widely used for the diagnosis of central precocious puberty, and life-threatening reactions to gonadorelin acetate are extremely rare. Herein, we described – to the best of our knowledge – the first pediatric case in which severe anaphylaxis was encountered after intravenous gonadorelin acetate administration. An 8-year-old girl who was diagnosed with central precocious puberty was receiving triptorelin acetate treatment uneventfully for 6 months. In order to evaluate the efficacy of the treatment, an LH-RH stimulation test with gonadorelin acetate was planned. Within 3 min after intravenous administration of gonadorelin acetate, she lost consciousness and tonic seizures began in her hands and feet. She was immediately treated with epinephrine, diphenhydramine, and fluids. Her vital signs recovered within 30 min. Based on the results, anaphylaxis should be anticipated and the administration of these drugs should be performed in a setting that is equipped to deal with systemic reactions.

scholarly journals Retrospective Comparison of Intramuscular Admixtures of Ketamine and Dexmedetomidine Versus Ketamine and Midazolam for Preoperative Sedation

2020 ◽  
Vol 68 (1) ◽  
pp. 3-9
Author(s):  
David B. Guthrie ◽  
Martin R. Boorin ◽  
Andrew R. Sisti ◽  
Ralph H. Epstein ◽  
Jamie L. Romeiser ◽  
...  
Keyword(s):  
Chart Review ◽  
Control Group ◽  
Time Interval ◽  
Efficacy And Safety ◽  
Control Groups ◽  
Retrospective Comparison ◽  
Significant Difference ◽  
Dental Rehabilitation ◽  
Intraoperative Period ◽  
And Control

Precooperative children and patients with intellectual disabilities often require intramuscular (IM) sedation prior to the induction of general anesthesia (GA). Ketamine is an effective preinduction sedative but can produce significant adverse side effects. Dexmedetomidine, a sedative with sympatholytic and analgesic properties, may provide advantages when used in combination with ketamine. This retrospective study evaluated the efficacy and safety of IM ketamine with dexmedetomidine for preoperative sedation. We conducted a chart review of all patients (n = 105) treated for dental rehabilitation who received either IM ketamine and dexmedetomidine (study group, n = 74) or IM ketamine and midazolam (control group, n = 31) prior to induction of GA. No significant difference (p = .14) was observed in the time interval from IM administration to operating room entry (median [interquartile range]) between the study and control groups (5 [4–8] vs 5 [2–7] minutes). Patients who received IM dexmedetomidine exhibited significantly lower mean arterial pressures throughout the induction (p = .004) and had lower heart rates (p = .01) throughout the intraoperative period compared with patients who did not receive dexmedetomidine. The combination of dexmedetomidine and ketamine may provide effective and safe IM sedation prior to the induction of GA.

Sign in / Sign up

Export Citation Format

Share Document